Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 17;12(14):4731.
doi: 10.3390/jcm12144731.

Principles of Rational COVID-19 Therapy in Pediatrics

Oksana D Nemyatykh  1 , Marina A Maistrenko  2 , Dina D Demchenko  1 , Igor A Narkevich  1 , Sergey V Okovityi  3 , Vladimir N Timchenko  4
Affiliations
Review

Principles of Rational COVID-19 Therapy in Pediatrics

Oksana D Nemyatykh et al. J Clin Med. .

Abstract

The purpose of this review was to conduct a comparative assessment of the concepts of therapy for pediatric patients with COVID-19 in the framework of global clinical practice. A structural analysis of the range of drugs and treatment strategies in the context of etiotropic, pathogenetic, and symptomatic therapy has shown that in the global context and in real clinical practice, the etiotropic-pathogenetic approach based on information about the effectiveness of individual medical technologies prevails today. It has been established that eight international nonproprietary/grouping names are present in international practice as means of etiotropic therapy for pediatric patients with COVID-19, and 18 positions are used for pathogenetic therapy. In terms of frequency of occurrence, the leading positions are occupied by remdesivir and the combination of nirmatrelvir with ritonavir, as well as dexamethasone and tocilizumab. The paper emphasizes the relevance of research in the field of evaluating the effectiveness of individual treatment regimens as well as the analysis of the delayed consequences of pathology suffered in childhood under the conditions of using various approaches to pharmacotherapy.

Keywords: COVID-19; drug provision; pediatrics; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Ladhani S.N., Amin-Chowdhury Z., Davies H.G., Aiano F., Hayden I., Lacy J., Sinnathamby M., de Lusignan S., Demirjian A., Whittaker H., et al. COVID-19 in children: Analysis of the first pandemic peak in England. Arch. Dis. Child. 2020;105:1180–1185. doi: 10.1136/archdischild-2020-320042. - DOI - PMC - PubMed
    1. Parri N., Lenge M., Buonsenso D., Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group Children with COVID-19 in Pediatric Emergency Departments in Italy. N. Engl. J. Med. 2020;383:187–190. doi: 10.1056/NEJMc2007617. - DOI - PMC - PubMed
    1. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed
    1. Public Health Ontario COVID-19 Infection in Children: January 15, 2020 to June 30, 2021. [(accessed on 18 May 2021)]; Available online: https://www.publichealthontario.ca/-/media/documents/ncov/epi/2020/05/co....
    1. Nikolopoulou G.B., Maltezou H.C. COVID-19 in Children: Where do we Stand? Arch. Med. Res. 2022;53:1–8. doi: 10.1016/j.arcmed.2021.07.002. - DOI - PMC - PubMed

LinkOut - more resources